01—Abstract
Summary
Summary of the 10-K filed February 26, 2019. Cited figures are marked; the original filing is the authoritative source.
Medpace Holdings, Inc. (MEDP) reported total revenue of $704.6 milliona for 2018 under ASC 606, compared with $436.2 million in 2017, and net income of $73.2 million, or $1.97 per diluted share, versus $39.1 million in 2017.
The filing states that the increase was primarily driven by ASC 606 adoption, which added $155.2 millionb to 2018 revenue, with the remainder attributed mainly to strong Oncology and other therapeutic-area activity. On an ASC 605 basis, net new business awards were $581.0 million in 2018 and backlog was $626.1 million, up 19.4% from $524.4 million at year-end 2017. On an ASC 606 basis, backlog was $1,057.9 million, of which approximately $580 million to $600 million is expected to convert to revenue in 2019.
The most important disclosure for investors is that management concluded internal control over financial reporting was not effective as of December 31, 2018, due to a material weakness related to the implementation of ASC 606. The company has developed a remediation plan, but the filing notes it may not be fully implemented in a timely or effective manner. The company's auditor, Deloitte & Touche LLP, issued an unqualified opinion on the financial statements and describes the adoption of ASC 606 under the modified retrospective approach.
Balance sheet and capital structure items include cash and cash equivalents of $23.3 millionc, total debt of $80.4 million under the Senior Secured Term Loan Facility, and $149.8 million available under the undrawn Senior Secured Revolving Credit Facility at year-end. The filing also discloses a FINRA review of trading in the common stock surrounding the July 30, 2018 announcement of second-quarter 2018 results, and states that Dr. August J. Troendle, the CEO and founder, controls approximately 24.5% of outstanding shares.
02—Key points
Key Highlights
- Total revenue of $704.6 million in 2018 versus $436.2 million in 2017; the filing attributes $155.2 million of the increase to ASC 606 adoption.
- Net income of $73.2 million in 2018 ($1.97 diluted EPS), compared with $39.1 million ($0.98 diluted EPS) in 2017.
- Net new business awards were $899.4 million on an ASC 606 basis for 2018 and $581.0 million on an ASC 605 basis.
- Backlog of $1,057.9 million on an ASC 606 basis at December 31, 2018, with approximately $580 million to $600 million expected to convert to net revenue in 2019.
- Management identified a material weakness in internal control over financial reporting related to ASC 606 implementation, and concluded internal control was not effective as of December 31, 2018.
- Total debt of $80.4 million under the Senior Secured Term Loan Facility, with $149.8 million available under the undrawn Senior Secured Revolving Credit Facility as of year-end.
- Customer concentration: 69% of 2018 net revenue came from small biopharmaceutical companies and 24% from mid-sized companies; the top 10 customers represented 33.0% of net revenue.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2018filed February 26, 2019Financial Statements
FY2018 against FY2017
| Line item | FY2018FY2017 | Change |
|---|---|---|
| Revenue | $704.59M$436.15M | +61.5% |
| SG&A Expenses | $75.68M$63.36M | +19.5% |
| Operating Expenses | $603.54M$371.29M | +62.6% |
| Operating Income | $101.05M$64.86M | +55.8% |
| Net Income | $73.19M$39.12M | +87.1% |
| EPS (Basic) | $2.05$1.00 | +105.0% |
| EPS (Diluted) | $1.97$0.98 | +101.0% |
| Shares Outstanding (Basic) | 35.55M39.06M | −9.0% |
| Shares Outstanding (Diluted) | 36.91M39.84M | −7.3% |
05—Questions
Frequently Asked Questions
Why did reported revenue rise so sharply in 2018?
The filing states that the increase was primarily driven by the adoption of ASC 606, which resulted in an increase of $155.2 million in 2018 total revenue. The remaining increase was primarily driven by strong activity within the Oncology and other uncategorized therapeutic areas. Reimbursed out-of-pocket revenue was reported at $0.0 million in 2018 under ASC 606 because that presentation changed.
What is the material weakness, and what is the company doing about it?
Management concluded that internal control over financial reporting was not effective as of December 31, 2018, due to a material weakness related to the implementation of ASU No. 2014-09 (Topic 606). Specifically, the company did not maintain effective controls over the implementation of the new standard, including proper application of its new revenue recognition policies. Management has developed and is implementing a remediation plan, but the filing cautions that the plan may not be fully implemented in a timely or effective manner.
How concentrated is the customer base?
No single customer represented 10% or more of net revenue in 2018. However, the company derived 33.0% of net revenue from its top 10 customers and 5.8% from its largest customer. Small biopharmaceutical companies accounted for 69% of 2018 net revenue and mid-sized companies for 24%. The filing notes that these smaller companies may have limited access to capital.
How much of the backlog is expected to become revenue, and how reliable is it as a predictor?
On an ASC 606 basis, backlog was $1,057.9 million at December 31, 2018, and approximately $580 million to $600 million is expected to convert to net revenue in 2019, with the remainder expected in later years. The filing states that most customer contracts can be terminated without cause on 30 days' notice, so backlog may not be a meaningful predictor of future results and may not convert at historical rates.
What are the key debt and ownership considerations for investors?
The company had $80.4 million outstanding under its Senior Secured Term Loan Facility and no borrowings under its revolving facility at year-end, with $149.8 million available for borrowing. The credit agreement contains financial covenants and is secured by substantially all assets. The filing also states that founder and CEO Dr. August J. Troendle controls approximately 24.5% of outstanding common stock, which the company says gives him significant influence over matters requiring shareholder approval.
06—Continue